Compare SON & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SON | LQDA |
|---|---|---|
| Founded | 1899 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.5B |
| IPO Year | 2014 | 2020 |
| Metric | SON | LQDA |
|---|---|---|
| Price | $59.37 | $68.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $60.13 | $41.00 |
| AVG Volume (30 Days) | 1.0M | ★ 1.6M |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | ★ 510.30 | 51.81 |
| EPS | 0.68 | ★ 1.26 |
| Revenue | ★ $7,518,753,000.00 | $158,320,000.00 |
| Revenue This Year | $0.10 | $278.87 |
| Revenue Next Year | $1.82 | $57.13 |
| P/E Ratio | $85.78 | ★ $56.39 |
| Revenue Growth | 41.72 | ★ 1031.18 |
| 52 Week Low | $38.65 | $21.15 |
| 52 Week High | $60.67 | $93.61 |
| Indicator | SON | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 60.66 | 35.96 |
| Support Level | $46.53 | $31.99 |
| Resistance Level | $60.67 | $92.35 |
| Average True Range (ATR) | 1.26 | 4.75 |
| MACD | -0.07 | -2.21 |
| Stochastic Oscillator | 94.05 | 2.84 |
Sonoco Products Co is engaged in the manufacture and supply of consumer and industrial packaging products, offering paper, metal, and plastic packaging solutions across multiple end markets. The company has two reportable segments: Consumer Packaging and Industrial Paper Packaging. The Consumer Packaging segment provides rigid packaging solutions mainly for food, beverage, household, personal care, and pharmaceutical products, while the Industrial Paper Packaging segment produces paper-based packaging materials such as tubes, cores, and protective packaging, supported by paper mills and recycling operations, serving industrial and consumer markets. It generates the majority of its revenue from the Consumer Packaging segment.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.